Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ACRSthis companyAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ALDXAldeyra The	$0.66	-9.25×	7.03×	0×	-8.1×	55.2%	0.0%	0.0%	0.0%	-76.5%	-59.0%	-10.7%	0.35×	1.72×	-18.51×	2.58×	0.0%	2	-12.88	2	B-
ALMSAlumis Inc.	$6.39	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ATATTOAttovia Therapeutics, Inc.	$16.29	-15.42×	6.25×	698.03×	-13.67×	-93.5%	40.4%	-4974.7%	-4490.9%	-40.2%	-42.8%	-6.5%	0.03×	0.53×	0×	14.2×	0.0%	—	—	2	C
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
Peer median	—	-9.25×	7.03×	3.83×	-8.1×	-91.8%	40.4%	0.0%	-5.6%	-40.2%	-42.8%	-6.5%	0.12×	0.21×	0×	4.34×	0.0%	2	-2.67	2	—